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INTRODUCTION 
In this thesis I have demonstrated that circulating immune complexes 
occur in patients with Lyme arthritis. These complexes have a number 
of special features that are of particular interest to rheumatologists 
and clinical immunologists as they search for the cause of rheumatoid 
arthritis. Nearly all patients at the onset of disease had these immune 
complexes which became less prevalent with time and rarely present during 
periods of remissions. They contained Clq reactive IgG, had a density 
near 19S, and were partially cryoprecipitab 1e. It is likely that they 
contained an antigen related to the causative agent of Lyme arthritis. 

PRELUDE 
The search for the causative agent of Lyme arthritis has involved 
the Yale University School of Medicine, the United States Public Health 
Service, and the Connecticut State Health Department. The initial 
investigation of the epidemiology and the clinical manifestations of 
Lyme arthritis was conducted by the Rheumatology Section of the Department 
of Medicine, the Department of Pediatrics, and the Department of Epidemio¬ 
logy and Public Health at Yale University School of Medicine. The 
methods for conducting this investigation were approved by the Human 
Investigation Committee (Protocol #1125). Further investigations were 
greatly aided by Dr. S. Ruddy from the Medical College of Virginia who 
measured serum complement levels and Drs. L. C. Walker and R. C. Williams 
from the University of New Mexico School of Medicine who tested serum 
samples using the Raji cell and Clq solid phase assays. 
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I. LITERATURE REVIEW 
A. LYME ARTHRITIS 
Lyme arthritis is a new disease which was first recognized in 1975- 
Retrospect i ve 1 y no cases have been identified prior to 1972 (1). The 
initial clue that led to the discovery of this disease came from two 
women who, concerned about recent attacks of arthritis among their chil¬ 
dren, independently called the Connecticut State Health Department to 
report that they believed an epidemic of juvenile rheumatoid arthritis 
(JRA) was occurring in their small community of Lyme, Connecticut (1). 
Health Department officials subsequently contacted members of the Rheuma¬ 
tology Section at Yale University School of Medicine. This series of 
events triggered a retrospective study by members of the Yale Rheumatology 
Section to identify all residents of Lyme, Connecticut and neighboring 
communities with acute onset of arthritis. 
In this initial retrospective study of 51 patients,Lyme arthritis 
was defined as a new clinical entity characterized by o1igoarticu1 ar 
arthritis and geographical clustering. Although previously misdiagnosed 
as juvenile rheumatoid arthritis or rheumatoid arthritis (RA), Lyme 
arthritis was distinct because of the geographical clustering and the 
seasonal onset of the arthritis, June to September. About one quarter 
of the patients reported an expanding annular rash before the onset of 
arthritis. Nearly all of the 51 patients resided within one of three 
communities in eastern Connecticut: Lyme, Old Lyme, and East Haddam. 
One in ten children living on four country roads were affected. 
-1- 
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Since Lyme arthritis occurred seasonally, Steere et al (2) began a 
prospective study of 32 patients with new onset of disease in 1976. In 
this study the skin lesion, erythema chronicum migrans (ECH)»was clini¬ 
cally the most diagnostic feature of Lyme arthritis (2). Although this 
unique skin lesion has been observed in the U.S.A. on only a single 
occasion (3), multiple reports have described its occurrence in Europe 
where it has been associated with neurological symptoms but not with 
arthritis (A-10). Lyme arthritis patients have had neurological symptoms 
-- peripheral and central nervous systems -- in addition to cardiac 
symptomatology. 
Skin: The initial lesion, ECM, was reported by about one third of 
patients to begin at the site of a tick bite. The lesion first appeared 
as a small red macule that expanded to form a large annular rash with an 
intense red border, partial central clearing, and an indurated center. 
After the initial lesion, some patients developed multiple smaller 
satellite lesions without an associated tick bite and without central 
induration. Scaling was not prominent and mucosal surfaces were not in¬ 
volved. Malaise and fatigue, chills and fever, headache and stiff neck 
were the most common symptoms associated with or preceding the skin 
lesion. On physical examination, patients often had elevated tempera¬ 
tures and less frequently 1ymphadenopathy, splenomegaly, malar rash, 
and periorbital edema. 
Skin biopsy specimens from the center of the lesion showed heavy 
mononuclear cell infiltrates around blood vessels and skin appendages 
throughout the dermis. Thickened keratin, edema, and hemosiderin depo¬ 
sits were characteristic of epidermal changes. Unlike the center the outer 
border of the lesion showed only dermal changes. 
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Joints: Of the prospectively studied patients, 27 were studied 
from the beginning of their joint symptoms or before. These patients 
with arthritis frequently (19 of 27, 70%) had the onset of ECM a median 
of A weeks (0.6 - 22 weeks) previously. Patients usually noticed the 
sudden onset of an asymmetric arthritis in a few joints, most frequently 
the knee. However, some patients had migratory arthralgias. The dura¬ 
tion of the arthritis was characteristically short (median 8 days), 
separated by longer periods of remission. At examination, affected knees 
were typically hot, but rarely red, and often very swollen with occasional 
formation and rupture of Baker's cysts. The synovium in Lyme arthritis 
had changes identical to those of rheumatoid arthritis, namely hyper¬ 
trophy, vascular proliferation, and mononuclear cell infiltration. 
Central Nervous System: As many as one third of the prospectively 
studied patients had symptoms suggestive of aseptic meningitis -- fever, 
headache, and stiff neck during the first few days of the illness. Two 
patients had severe recurrent headaches and stiff necks with lymphycytic 
meningitis confirmed by lumbar puncture. 
Peripheral Nervous System: In addition to arthritis, three patients 
developed cranial nerve palsies. Of the two patients with Bell's palsy, 
one had a sensory radiculopathy over the T10 dermatome. The third patient 
had unilateral ptosis in addition to lymphocytic meningitis. The abnor¬ 
malities commonly lasted for months but usually resolved completely. 
Heart: After the skin lesion some patients developed myocardial 
conduction abnormalities such as first degree, Wenckebach, third degree 
atrioventricular, and alternating bundle branch blocks. Patients had 
reduced cardiac ejection fraction by Technetium sulfur colloid scans at 
the time of their conduction defects. None of the patients had evidence 
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of streptococcal infection although two did satisfy the Jone's criteria 
for rheumatic fever. 
Etiology: Occasional reports have suggested that patients with ECM 
have antibodies against viruses (9, 11) or rickettsia (12, 13) but they 
have not been confirmed in subsequent studies (lA, 15)- Despite the 
use of extensive methods no viruses or bacteria were detected in cultures 
of biological samples from patients with Lyme arthritis, and serologic 
tests -- including tests for 216 arboviruses, 38 of which are known to 
be carried by ticks -- did not suggest infection with agents known to 
cause other forms of arthritis. Serum analysis for rheumatoid factor 
(RF) and antinuclear antibodies (ANA) were almost invariably negative (2). 
Epidemio1ogy: The three affected Connecticut communities were 
sparsely populated areas bordering the Connecticut River. Most patients 
in these communities lived on large wooded lots or farms. A tick bite 
was recalled at the site of the lesion by several patients, and epidemio¬ 
logical analysis of the arthritis clusters suggested transmission of a 
causative agent by an arthropod vector (1, 2, 16). The location of the 
lesion on the trunk and proximal exthemities, also favored a crawling 
arthropod. Unlike the pattern of airborne spread, family members usually 
had onset of the disease during different years (1, 2). The time of on¬ 
set of ECM, from May to August, was also consistent with an arthropod 
vector (2). 
Lyme arthritis has resembled immune complex disorders in clinical 
manifestations of disease and in clinical response to steroid treatment. 
Furthermore, sera from patients with ECM and cryoglobulins had lower 
complement levels and were more likely to develop arthritis than patients 
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with ECM alone (2, 17)- These findings were indirect evidence that 
immune complexes might play a role in the pathogenesis of Lyme 
arthritis. 
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B. IMMUNE COMPLEXES AS MEDIATORS OF TISSUE INJURY 
Immune complexes are defined as the combination of an antibody 
and an antigen. The nature and the quantity of immune complexes are 
dependent on the dynamics of formation, clearance mechanisms, and tissue 
deposition. The formation of these complexes is part of normal physio¬ 
logy but the untoward activation of immune mechanisms may lead to disease. 
As summarized by Caldwell (18), the formation of immune complexes 
depends on: number of binding sites available, antibody affinity, 
and antigen to antibody ratio. The number of binding sites depends on 
the valency of the antibody and the number of determinants on the anti¬ 
gen. The normal antibody affinity varies 1012 to 104 liters per mole. 
Antibody affinity depends on the type of immunoglobulins (i.e. IgG has 
greater affinity than IgM) and the temperature. (Cold-antibodies have 
increased affinity for antigen at lower temperatures.) Complexes formed 
near the equivalence point, 1:1 ratio of antigen and antibody, have greater 
lattice formation and therefore greater size than complexes formed at 
other ratios. The complexes may be modified after formation by complement 
and by cells which bind to the Fc receptor of immunoglobulins. 
Immune complexes are formed in circulating blood or in tissues. The 
large circulating complexes fix complement and are readily cleared by 
the phagocyte system (19). Small complexes are less efficiently cleared 
-- to some extent by the spleen -- or they are deposited in renal 
glomeruli, blood vessel walls, or choroid plexus (20, 21). 
Immune complexes can form in tissue by several mechanisms. In the 
Arthus type reaction, antigen present locally reacts with circulating 
antibody. The immune complexes involved in the glomerulonephritis of 
Goodpasture's syndrome are formed by circulating antibody reacting with 
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glomerular basement membrane (GBM) as the tissue bound antigen (22). 
Antibody and antigen can both be released locally to form immune com¬ 
plexes, i.e. late granulomas with shistome eggs (23). 
Immune complexes with the greatest pathogenetic potential are pri¬ 
marily those that can activate complement or react with various cell 
types via immunoglobulin (Fc) or complement receptors. Following immune 
complex binding to Fc receptors, cell mediated tissue damage results 
from phagocytosis (2A) or exocytosis with release of vasoactive amines 
(25). Immune complex binding of complement triggers the production of 
activated complement components which can lyse cells (26, 27) or recruit 
leukocytes to cause tissue injury (22, 25, 28). 
The importance of complement activation as a cause of tissue damage 
can be demonstrated in vivo, for instance, inflammation of an Arthus 
reaction can be prevented by prior C3 depletion with cobra venom. Cell 
lysis results when immune complexes are brought in close apposition with 
cell membranes or are formed between antibody and a cell membrane bound 
antigen. The terminal components can directly lyse the cell or indirect¬ 
ly lyse a bystander cell (26, 27). Activated complement components can 
recruit leukocytes by initiating leukocyte migration (components C567 
and C5a [22], binding (component C3b [28], and exocytosis (components 
C3b and C5a [25]). 
Tissue damage also results from immune complex activation of leukocytes, 
platelets, and lymphocytes via the Fc receptor. Neutrophile phagocytosis 
is initiated by only those complexes formed between an antigen and IgG1, 
and I gG3- All subgroups of Ig G in addition to IgA can stimulate neutro¬ 
phile exocytosis with release of granules containing proteolytic enzymes 
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and basic peptides (25). These enzymes and peptides result in increased 
vascular permeability and activation of the clotting system (25). John¬ 
son et al (29) used millipore filters coated with IgG as a model of immune 
complexes to show that the release of toxic oxygen metabolites and re¬ 
lease of granules are stimulated by immune complexes. The factors 
released by neutrophile exocytosis probably result in much of the tissue 
injury that occurs in human inflammation; dependance upon neutrophiles 
for the development of the inflammatory manifestations of serum sickness 
arteritis (28, 29), Arthus reactions (30, 31) and antibody mediated 
nephritis (32) has been described. 
The interaction of immune complexes with macrophages has only recent¬ 
ly been studied although they are a constant feature of inflammatory 
reactions (33)- Mononuclear phagocytes have receptors which have greater 
affinity for the Fc region of IgG1 and IgG3 than !gG2 or lgG4; attachment 
of antibody-coated cells to these receptors is followed by phagocytosis 
(24). Similar to neutrophiles, the exposure of macrophages to immune 
complexes is accompanied by selective release of macrophage lysosomes 
(34). Moreover, the ability of macrophages to contribute to inflammation, 
i.e. in arthritis (35), has been demonstrated in animal models. 
Basophiles and mast cells, however, require immune complexes with 
IgE and to a lesser extent IgG to stimulate exocytosis (38). Basophile 
granules contain vasoactive substances (slow reacting substance of 
anaphylaxis, and eosinophilic chemotaxtic factor of anaphylaxis), factors 
affecting the clotting system, and platelet activating factor (36). An 
IgE-mediated anaphylactic response often accompanies the deposition of 
immune complexes and appears to be responsible for the deposition in 
arteries and glomeruli (20). 
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Human platelets bear Fc receptors for IgG 1, 2, 3 and ^ but not 
for other classes of immunoglobulin or for complement (25)- Immune 
complexes bind via this receptor to induce platelet clumping and release 
of vasoactive amines (25)- These amines increase vascular permeability 
which may be essential in allowing circulating immune complexes to be¬ 
come trapped in vessel walls (20). 
Human peripheral blood lymphocyte cells are a heterogenous popula¬ 
tion consisting of T cells which mediate cellular immunity, B cells 
which mediate humoral immunity, and a third cell population defined by 
its ability to lyse target cells coated with antibodies (37, 38). This 
third population, generally referred to as killer or K cells, may cause 
tissue destruction by the mechanism of antibody-dependent ce11-mediated 
cytotoxicity. K cells appear morphologically similar to small lympho¬ 
cytes but they lack the surface markers normally associated with mature 
T and B cells (36). Instead, K cells possess receptors for the Fc portion 
of IgG and for C3 (37)- In order to lyse target cells, K cells must bind 
to the Fc receptor of antibodies attached to the target cell. This 
mechanism of tissue destruction has been demonstrated to occur in auto¬ 
immune diseases such as Hashimoto's thyroiditis (38, 39)- 
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C. IMMUNE COMPLEXES IN HUMAN DISEASE 
The clinical features of immune complex disease depend on the 
position and the deposition of the complexes. The composition of the 
complexes varies with the nature of the antibodies and antigens involved. 
In systemic lupus erythematosus for instance, evidence from animal models 
suggests that antibodies with weak affinity are formed (40); the low 
affinity antibody results in the formation of complexes which are more 
likely to escape the phagocyte system (4l). The affinity of DNA for 
collagen (42) may explain the glomerular membrane deposits of DNA-antiDNA 
and therefore the nephritis in systemic lupus erythematosus. The deposi¬ 
tion of immune complexes depends on whether they are formed in body fluids 
as circulating immune complexes or in body tissues. Circulating immune 
complexes are either cleared by the mononuclear phagocyte system or 
deposited in renal glomeruli, choroid plexus or vessel walls (20, 21). 
Circulating complexes which are small (19)> which do not bind complement 
(19) or which are composed of antibodies with low affinity for antigen (41) 
are more likely to evade the phagocyte system and be deposited. Immune 
complexes which are formed in tissues result in an Arthus reaction, and 
the site of inflammation will vary with the method of antigen deposition, 
i.e. injected into the skin, inhaled into the lungs, released into 
tissues by parasites, etc. (43). 
Diseases associated with immune complexes are a very large and 
diversified group. They are most conveniently categorized by the origin of 
the antigen, endogenous or exogenous. Endogenous antigens include IgG of 
rheumatoid arthritis, nuclear antigens of systemic lupus erythematosus, 
and cell specific antigens of tumors and autoimmune diseases. Among the 

exogenous antigens are infectious agents (viruses, bacteria, etc.), 
environmental causes (pollens, dusts, etc.) and introgenic causes (the 
proteins of serum sickness, drugs, etc.). Well studied and representa¬ 
tive immune complex diseases that are pertinent to this thesis include 
rheumatoid arthritis, systemic lupus erythematosus, hepatitis B, and 
dengue hemorrhagic fever. 
Rheumatoid Arthritis: Clinically, rheumatoid arthritis is charac¬ 
terized by destructive joint disease with less frequent systemic mani¬ 
festations, i.e. subcutaneous nodules, vasculitis, pulmonary fibrosis, 
and pericarditis but rarely kidney lesions. The arthritis usually 
involves the small joints in a symmetrical fashion. The incidence of 
rheumatoid arthritis increases with age, and is sex related because 
women are affected twice as frequently as men. 
The formation of immune complexes and the activation of the comple¬ 
ment system are known features of rheumatoid arthritis. Many of the 
techniques -- both direct and indirect -- for the study of immune com¬ 
plexes were developed in the search for the pathological mechanism of the 
disease. Immunof1uorescent staining has provided indirect evidence of 
immune complexes in tissues. Using these staining techniques, Fish (44) 
and Rodman (45) demonstrated IgG, IgM and complement in synovial membranes 
of patients with rheumatoid arthritis. Similar deposits have been found 
in rheumatoid nodules (46), nerve tissue (47) and vessel walls (48). 
Subsequently, Franco and Schur (49) and Hunder and McDuffie (41) reported 
low complement levels in rheumatoid arthritis patients, evidence which 
suggested complement consumption by immune aggregates. 
Direct evidence of the presence of immune complexes in rheumatoid 
arthritis had been provided as early as 1957 by Franklin et al (51) who 
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demonstrated by analytical ultracentrifugation the presence of a high 
molecular weight material (22S) in the serum of rheumatoid arthritis 
patients. That immune complexes possessing biological activity might 
be present in rheumatoid arthritis has been shown by Baumal and Broder 
(52) who isolated high molecular weight material, rheumatoid biologi¬ 
cally active factor (RBAF), capable of initiating a complement dependent 
reaction resulting in the release of histamine from guinea pig lung. 
This materia], RBAF, was present in sera and joint fluid, and it corre¬ 
lated with disease activity (53)- A simpler technique for demonstration 
of immune complexes was introduced in 1967 by Hamstead (54). He found 
that certain high-titer rheumatoid factors (RFs) capable of precipitating 
aggregated IgG, produced precipitin reactions with rheumatoid synovial 
fluid. Winchester et al (55) reported that monoclonal rheumatoid factors 
(mRFs) were superior for demonstrating this material. 
All these techniques have certain drawbacks that limit their use¬ 
fulness in studying the relationship of immune complex-like material 
to disease. Analytical ultracentrifugation is relatively insensitive 
and too cumbersome for analysis of larger numbers of samples. The bio¬ 
assay technique of Baumel and Broder is very complex and undoubtedly 
will prove difficult to standardize. Immunodiffusion is nonquantitative 
and weak bands are difficult to determine with confidence. Therefore, 
investigators have developed a new generation of assays involving radio¬ 
immunoassays, i. e. the 125l-Clq binding assay by Zubler et al (46) and 
the mRF assay by Luthra et al (47). 
Rheumatoid arthritis patients more frequently had positive tests 
with the 125l-Clq binding assay, 76% of synovial fluids and 63% of sera, 
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than with the other assays (56, 57, 58). The Clq reactive material sedi¬ 
mented with a density of 10-34S with the maximum amount of material 
sedimenting at 1 -15S (56). There was no correlation between the amount 
of immune complexes detected in the assays and RF titers (56, 57, 58). 
However, the results of the assays did show a negative correlation with 
the levels of complement component C4 (56, 57). 
Although C4 levels were often depressed to the lower limits of nor¬ 
mal in rheumatoid arthritis patients, the levels of most complement 
components have been generally normal or elevated in this disease (59, 60, 
61). Elevated complement levels might be explained by an increased 
synthesis of complement which is often seen in inflammatory disease (61) 
probably associated with increased catabolism as suggested by radio- 
labelled turnover studies of complement (62). Nydegger et al (63) found 
elevated levels of C3d in the sera and joint fluids of patients with 
rheumatoid arthritis which correlated with the amount of Clq reactive 
material in patient materials but not with RF titers. These results 
strongly suggest the presence of immune complexes and the activation of 
complement in these biological fluids. The C3d levels in synovial fluid 
were higher than and only poorly correlated with the C3d level in serum. 
This observation was consistent with parallel activation of complement 
in synovial fluid and serum. 
The major antigen in immune complexes of rheumatoid arthritis was 
assumed to be IgG but this theory is now questionable. Synovial lympho¬ 
cytes produce an IgG that is recognized as foreign by the body (64). 
Rheumatoid factors (RFs), IgM type anti-IgG and IgG type anti-IgG, are 
produced in response to the antigenica11y active IgG, IgG*, immune com¬ 
plexes then form between RF and IgG* (64). Studies of IgG* have 
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demonstrated that a defect exists in the hinge region of the immunoglo¬ 
bulin and that the defect is also responsible for the abnormal avidity 
of IgG-for B lymphocytes (65). In some 1ymphoproliferative diseases a 
monoclonal rheumatoid factor (mRF) of the IgM type is produced. The 
IgM RF can bind up to five lgG*s to form complexes thought to have 
pathological potential. However, the participation of 19S RF in at least 
complexes that bind Clq appears limited since the concentration of the 
Clq reactive material does not correlate with RF titers and the density 
of the Clq reactive material, 1A-15S, is less than that of IgM RF (56). 
Some investigators have suggested that RF has a role in the pathogenesis 
of rheumatoid arthritis by enhancing the antibody-dependent ce11-mediated 
cytotoxicity (ADCC) (65)- However, Feldmann et al (66) have found the 
ADCC to be normal in rheumatoid arthritis. 
Other materials such as cell proteins, collagen, and virus particles 
have been implicated as the antigen in the immune complexes of rheumatoid 
arthritis. Some evidence indicates that proteins in lymphocyte membranes 
or nuc1eoproteins may have antigen activity in rheumatoid arthritis (67). 
Many investigators have suggested that collagen is an important antigen 
in rheumatoid arthritis. Evidence by Steffen et al (68) demonstrates 
that anticollagen antibodies are present in more than one third of sera 
from patients with rheumatoid arthritis. Using collagen digesting techni¬ 
ques, Mentzel et al (69) has shown that co11agen-anticol 1agen antibodies 
are present in the synovial fluids of rheumatoid arthritis patients. 
An animal model of arthritis can be produced by the injection of collagen 
into the knee joints of collagen immunized animals (70). Viruses have 
also been implicated in the disease because of the decreased sensitivity 
of rheumatoid synovial cells to infection by Newcastle and ruebella 
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viruses (67) • 
Both the direct and indirect methods for detecting immune complexes 
have shown a correlation with disease activity. Though Zubler et al 
(56) did not find a correlation between the amount of Clq reactive mater¬ 
ial in serum and disease stage, he did find a positive correlation between 
the presence of systemic disease and the presence of Clq reactive material. 
Nydegger et al (63) found that the C3d levels correlated with a disease 
index which took into account the joint score, morning stiffness, and 
erythrocyte sedimentation rate. The difficulty in correlating disease 
activity with the concentration of reactive materials in the assays may 
result from the parallel activation of synovial fluid and serum. Further¬ 
more, the production of immune complexes and the activation of complement 
in each joint is most likely independent from other joints. Therefore, 
assay results from synovial fluid obtained from one joint would not reflex 
the disease activity in other joints. 
Systemic Lupus Erythematosus (SLE): Systemic lupus erythematosus 
is characterized by malar skin rash, arthritis, vasculitis, pleuritis, 
pericarditis and nephritis. The most frequent cause of death in this 
disease is the complications of renal failure. The clinical diagnosis 
of SLE is aided by positive LE preparations and antinuclear antibody 
(ANA) titers. 
Indirect evidence of DNA-antiDNA complexes in renal glomeruli was 
demonstrated in 1967 by Koffler (71) using elution and immunohistochemi- 
cal techniques. Atkins et al (72) demonstrated similar complexes in the 
choroid plexus of SLE patients. Additional evidence of immune complexes 
was demonstrated by Winchester et al (73) who showed a correlation between 
complement depletion and immune complexes in the sera and synovial fluids 
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of SLE patients. 
Direct evidence of immune complexes in SLE was first provided by 
Agnello (7*0 who demonstrated Clq precipitation of immune complex-like 
material using immunodiffusion techniques. Recently developed radio¬ 
immunoassays , i . e . 1 2 1 I -C 1 q binding assay (75, 76), Clq deviation assay 
(58), mRF assay (58), and Raji cell assay (77) have frequently detect 
ed immune complexes in the sera of patients with SLE. All patients with 
SLE tested by the Raji cell assay had positive results (77) a larger 
percentage than the bS% reported by Gabriel using the Clq deviation assay 
(57). Results of both assays had positive correlations with ANA titers 
and negative correlations with complement levels (57, 77). Agnello et 
al (58) and Levinsky et al (78) found large and small complexes of 19S 
and 7S densities respectively. In addition, Levinsky et al (78) found 
intermediate size complexes which correlated with the presence of renal 
disease. 
Evidence of complement activation has been demonstrated by Nydegger 
et al (75), Theofi1opou1 os et al (77), and Agnello et al (58). These 
investigators noted a negative correlation between the CH50 levels and 
the presence of immune complexes. Levinsky et al (78) also noted depress 
ed levels of Clq in SLE patients. Perin et al (79) demonstrated elevated 
levels of C3d and Ba fragment of properidon indicating that classical 
and alternate pathways were involved probably resulting from immune com- 
plex activat ion. 
Nuclear antigens have been suspected of being involved in immune 
complex formation since the discovery of LE preparations and their 
correlation with the diagnosis of SLE. The titers of ANA also have 
correlated with disease activity. Disease activity and positive tests 
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for immune complexes correlated best with the titers of anti-sDNA (75). 
The presence of antibodies to sDNA and DNA:RNA have suggested a viral 
etiology, and oncornavirus (80) and reovirus (81) have been implicated 
in this disease. However Cano et al (82) demonstrated that only 3 of 11 
sera pretreated with DNase had lower amounts of Clq reactive material 
when compared to controls. This observation suggested that antigens other 
than DNA or RNA may be involved in systemic lupus erythematosus. Evidence 
to support this possibility has been the presence of several other auto¬ 
antibodies, i.e. anti1ymphocyte and anti-immunog1obu1in antibodies (64). 
Search for the cause for lymphocyte production of auto-antibodies 
has lead to the investigation of possible T and B cell defects in SLE. 
Many of these experiments have used New Zealand black and white mice 
(NZB and NZW respectively) because like SLE patients they have positive 
ANA titers and develop nephritis. Fye et al (64) have summarized the 
evidence implicating defective T cell function in systemic lupus erythema¬ 
tosus. These antibodies kill T cells or bind their receptors and block 
their function. This evidence correlated with the deficiency of suppres¬ 
sor T cells noted in NZB mice. Furthermore, T cell function decreases 
with age in these animals. New Zealand black mice treated with thymic 
hormone have prolonged T cell function and delayed onset of the nephritis. 
The decrease in suppressor T cells correlated with enhanced B cell acti¬ 
vities in NZB mice. Mice treated with a 1ymphocytotoxic agent, L-aspara- 
ginase, have decreased numbers of B cells and delayed onset of the 
nephritis (83)• 
An abnormality of K cell function, the antibody-dependent cell- 
mediated cytotoxicity (ADCC), in patients with systemic lupus erythema¬ 
tosus has also been observed. There appeared to be a "blocking factor" 
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in patient sera which caused the decrease in the ADCC (66). This 
"blocking factor" was present in the same portion of sucrose gradients 
as immune complexes, and was removed when the serum was incubated with 
DNase and pronase or when IgG was removed -- features consistent with 
immune complexes (DNA-antiDNA) as the "blocking factor" (66). Moreover, 
the ADCC of patient sera correlated with the extent of disease activity 
(66). Whether the immune complex-mediated inhibition of ADCC is a 
specific factor in the pathogenesis of systemic lupus erythematosus or 
not has not been determined. 
The disease activity of patients with systemic lupus erythematosus 
has correlated well with the evidence for immune complexes. The material 
reactive in the radioimmunoassays for immune complexes and the anti-DNA 
antibody titers both correlated with disease activity. Gabriel et al 
(58) studied systemic lupus erythematosus patients longitudinally and 
found that immune complex levels and anti-DNA titers rose and fell in 
parallel with the exacerbations and remissions of disease. Levinsky et 
al (78) found that the size of immune complexes correlated with the mani¬ 
festation of disease; intermediate size complexes correlated with the 
presence of nephritis. 
In addition to the presence of immune complexes, studies with animal 
models have indicated that the onset of disease also correlates with the 
decrease in the clearance of immune complexes by the mononuclear phago¬ 
cyte system. Preceeding the onset of nephritis in NZB mice. Petty and 
Steward (^0) have demonstrated a decrease in the affinity of antibodies 
using the globin precipitation technique. Immune complexes composed of 
antibodies with low affinity for antigens would be less likely to be 
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cleared by the phagocyte system (41). Morgan and Steward (42) found that 
the macrophage clearance function of these mice also decreased prior to 
the onset of nephritis. The antibody affinity and the macrophage clear¬ 
ance might be key factors which determine whether or not circulating 
immune complexes will have pathogenic potential. 
Hepatitis B: Patients with hepatitis B infection have been noted to 
have one of several clinical manifestations. Patients with mild disease 
have experienced transient urticarial skin rash, polyarthralgias and 
clinical jaundice. These patients frequently had cryoglobulins in their 
sera (84). The persistance of disease could result in symptoms similar 
to chronic serum sickness with renal (85) and vascular (86, 87) lesions 
in addition to liver injury. 
In addition to direct evidence of immune complexes in serum hepatitis, 
laboratory evidence of immune complexes in this disease has also been pro¬ 
vided by immunoelectronmicroscopy, complement studies, cryoglobulin 
studies and studies of antibody-dependent cel 1-mediated cytotoxicity 
(ADCC). Using electron microscopy, Almeida and Watterson (88) demon¬ 
strated the presence of immune complexes in the sera of individuals with 
chronic active or acute hepatitis. A pattern of immunofluorescence which 
indicated the presence of 1gG, HBsAg and complement -- components likely 
to be involved in the formation of immune complexes -- has been identi¬ 
fied on the hepatocyte membrane and in the cytoplasm of liver cells in 
patients with chronic active hepatitis (89)- Gerber et al (90) used 
fluorescent antibody techniques to demonstrate that complexes of IgG and 
HBcAg were in the nuclei of hepatocytes from patients with chronic active 
hepatitis but not from patients with acute hepatitis. Deposits of HBsAg, 
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IgG and complement have been identified in vascular (91) and renal lesions 
(85) suggesting immune complex involvement in extrahepatic disease. 
Serum from patients with hepatitis B infection and with decreased 
complement levels, suggestive of depressed complement levels, 
was reported by Thiry et al (92). While Fordor et al (93) did not find 
a significant loss of total complement, complement components Cl and C3 
each exhibited titers below normal in about half of the patients with 
chronic active hepatitis. 
Another method for identifying immune complexes in hepatitis B has 
been the study of cryoglobulins. Mixed IgG-IgM cryoglobulins in serum 
have been considered evidence of circulating immune complexes (9^, 95)- 
Fordor et al (93) and Carella et al (98) have reported that cryoglobulins 
are present in patients with serum hepatitis. The hepatitis B virus has 
been identified in the cryoprecipitates of serum from patients with this 
disease (31). 
A recent correlation with the presence of immune complexes in hepati¬ 
tis B infections has been the ADCC. Fye et al (98) demonstrated that 
the ADCC was decreased in patients with serum hepatitis and that the 
decrease in the ADCC correlated with the presence of immune complexes as 
detected by the Raji cell assay. The return to normal of the ADCC with 
overnight incubation of the lymphocytes (allowing regeneration of the 
surface membranes and shedding of the membrane-bound material) suggested 
that the defect was due to cell membrane bound material. Furthermore, 
this ADCC "blocking factor" was present in the same portion of density 
gradients as the immune complexes. It was hypothesized that the "blocking 
factor" was immune complexes that bound the Fc receptors on killer (K) 
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cells to prevent the binding to and lysis of the target cell. The role 
of these blocking factors in the pathogenesis of serum hepatitis, i.e. 
a disruption of the immunoregu1atory system or just an epiphenomenon, 
has not yet been defined. 
Direct evidence of immune complexes in the sera of patients with 
hepatitis B infection was provided by Coller et al (99) using a radio- 
immunoprecipitation assay. Using the Raji cell assay Theofi1opou1 os 
et al (77) reported the presence of immune complexes in 53% of sera from 
patients with serum hepatitis; similarly Nydegger et al (59) reported 
positive tests with the 12 51 —C1q binding assay in 33% of patient sera. 
Theofi1opou1 os et al (77) demonstrated that fractionated sera from pa¬ 
tients, with positive tests for Australian antigen and with negative tests 
for immune complexes, had HBsAg, IgG and C3 in the middle portion of the 
gradient. However, sera from patients, with positive tests for the 
Australian antigen and with positive tests for immune complexes, had 
HBsAg, IgG and complement in the middle and lower fractions. This data 
was consistent with immune complexes containing the Australian antigen 
in the sera of patients with hepatitis B. 
Immune complexes important in the pathogenesis of serum hepatitis 
may form between one or more of the three antigens; HBsAg -- the virus 
coat protein, HGcAg -- the nucelocapside, and HBe; and their corresponding 
antibodies (100). Several studies have provided evidence to implicate 
HBsAg in the formation of immune complexes. Theofilopoulos et al (77) 
demonstrated the presence of HBsAg in the same portions of gradients of 
fractionated sera as immune complexes. In addition, immunof1uorescent 
studies demonstrated HBsAg bound to Raji cells {11). E1ectronmicroscopic 
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studies have shown hepatocytes coated with HBsAg (89). 
There is evidence that other antigens besides hepatitis B virus 
particles might be involved in the formation of immune complexes in serum 
hepatitis. Fodor et al (93) demonstrated that rheumatoid factors were 
present in the sera of about one third of patients with chronic active 
hepatitis. The presence of rheumatoid factor has suggested that an 
abnormal antigenica11y active IgG may be present. Moreover, other auto¬ 
antibodies, i.e. antinuclear, antimitochordria 1 and anti-smooth muscle 
antibodies, has indicated that additional antigens may be involved, but 
none of these humoral factors have liver specificity (93). 
The stage of disease in patients with serum positive for the Austra¬ 
lian antigen correlated with the reactivity of patient sera in assays for 
immune complexes. Theofi1opou1 os et al (77) demonstrated that serum from 
patients with acute disease had more reactive material in the Raji cell 
assay than serum from patients in the convalescent phase of the disease, 
and the sera from asymptomatic carriers rarely contained reactive 
material. The reactive material in the Raji cell assay showed a positive 
correlation with enzyme and bilirubin levels (77). The amount of free 
HBsAg has correlated inversely with the severity of hepatitis (101). 
The excess free antigen may have presented immune complex formation 
between antibody and antigen on hepatocytes thereby avoiding hepato¬ 
cellular damage (101). 
Dengue Hemorrhagic Fever (DHF): Dengue hemorrhagic fever is a 
serious manifestation of infection by one of four types of Dengue virus 
-- a group B arbovirus. Shock, petechie and proteinuria are the major 
features of this disease. The shock is the result of massive losses of 
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fluid, electrolytes, and colloid (102) and treatment with blood trans¬ 
fusions has reduced the fatality from 10% to 2%. 
Immunopathological reactions suggested to play a role in the patho¬ 
genesis of DHF have been summarized by the World Health Organization (101). 
A clinical argument in support of this role is that the majority of 
affected children display evidence of prior dengue virus infection. 
Infants less than one year old have had evidence of primary dengue infec¬ 
tion, and in these patients the presence of maternal antibody might be 
important. A mechanism has been suggested by which dengue virus repli¬ 
cation might be amplified during a second infection. Antibody against 
one strain of virus does not neutralize a different strain of virus, but 
increases its capacity to replicate with monocytes because virus-antibody 
complexes would attach more readily to the monocyte through the Fc 
receptor than would the free virus. 
Indirect evidence from immunohistochemica1 techniques and complement 
depletion studies and direct evidence from radioimmunoassays have impli¬ 
cated immune complexes in the pathogenesis of DHF. Characteristic of 
DHF is the massive activation of both classical and alternate complement 
pathways (103). Boonpucknavig et al (10^) has demonstrated the presence 
of virus antigen, IgM, and C3 in the glomeruli of children with DHF 
and proteinuria. Patients with DHF frequently have macu1opapu1ar and 
petechial skin lesions which have been demonstrated to contain virus 
antigen, IgM, and C3 (101). Theofi1opou1 os et al (77) using the Raji 
cell and Sobel et al (105) using the Clq deviation assay have provided 
direct evidence of immune complexes in the sera of patients with DHF. 
Theofilopoulos et al (77) reported that 63% of sera obtained from patients 
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in various stages of DHF had positive results in the Raji cell assay. 
The presence of immune complexes in DHF correlated with the stage 
of disease and the site of the lesion. Sobel et al (105) noted that the 
amount of Clq reactive material increased with disease activity. Theo- 
filopoulos et al (77) demonstrated that sera from patients with more 
advanced stages of disease more frequently had evidence of immune com¬ 
plexes when compared with sera from patients in the earlier stages of 
disease. Moreover, patients had evidence of immune complexes at the site 
of both skin and renal lesions. The process by which the shock syndrome 
is produced has not been fully explained, but the action of immune com¬ 
plexes to cause the release of vasoactive amines from platelets might be 
an important factor. 
In the summary of these immune complex disorders, the evidence sug¬ 
gests that investigative techniques detected immune complexes in patient 
materials and that the immune complexes were involved in the pathogenesis 
of the disease and not just an epiphenomenon. Proof that immune complexes 
were present in patients with disease has been provided by analysis of 
tissue and biological fluids from patients. Indirect evidence was demon¬ 
strated by immunohistochemica1 techniques showing the presence of 
immunoglobulins, complement and occasionally antigens in tissues. Comple¬ 
ment studies showing depressed levels or elevated levels of breakdown 
products have indicated consumption by immune complexes. Results of 
assays for immune complexes have frequently been positive with patients 
with disease but were rarely positive in controls. The densities of 
material reactive in these assays, i.e. the 14-15S complexes of rheumatoid 
arthritis (77), have correlated with that of immunoglobulins in vitro. 
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Furthermore, antigens such as HBs in hepatitis B, have been detected 
in the same sucrose density fractions which have material reactive in 
the immune complex assays (77)* 
Studies of immune complex disorders have demonstrated positive 
correlations between the presence of immune complexes and the disease 
activity and between the size and the site of deposition of the complexes. 
Both clinical, i.e. the disease index of systemic lupus erythematosus, 
and the laboratory assessment of disease, i.e. the bilirubin and enzymes 
of hepatitis B, of disease activity have correlated with the amount of 
reactive material in the immune complex assays. Moreover, Feldmann et 
al (66) and Fye et al (98) have demonstrated that the presence of immune 
complexes and the progression of disease activity correlated with 
decreases in the ADCC -- suspected to be the result of a "blocking effect" 
of immune complexes. Whether this "blocking effect" alters the mechanism 
of immune complex-mediated tissue injury or not remains to be determined. 
Levinsky et al (78) demonstrated a correlation between the presence of 
complexes of intermediate size and the presence of nephritis in patients 
with systemic lupus erythematosus. Finally, deposits of immune complexes 
were frequently present at the site of inflammation, i.e. the glomeruli, 
joints, skin, and choroid plexus. 
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D. DETECTION OF IMMUNE COMPLEXES 
Immune complexes may be present in serum, in synovial fluids, in 
other biological fluids, or in tissues; and methods suitable for the 
detection of the complexes at these various sites are often different. 
The tissue-bound complexes can be studied in tissues or removed and 
studied similar to circulating immune complexes using techniques that 
are either antigen-specific or antigen-nonspecific. When the antigen 
is unknown investigators must rely on assays which involve physical and 
biologic properties of immune complexes independent of the identity of 
the antigen. 
Detection of Immune Complexes in Tissue 
Immune complexes in tissues can be detected by techniques to visual¬ 
ize the complexes in the tissue or by methods to remove and quantitate 
either the antigen or the antibody. In hepatitis B, for instance, 
electronmicroscopy provides visualization of deposits of immune-complex 
like material consisting of HBs antigen , antibodies, and complement 
components (88). Indirect evidence of immune complexes in serum hepatitis 
and in other immune complex disorders can be obtained by techniques which 
stain tissues for immunoglobulin , antigen, or complement (89)* Antigens 
can be removed from tissues using elution techniques with subsequent 
quantification of the free antigen (71). On the other hand, antibody 
can be released from tissue using antigen destroying techniques, i.e. 
DNase to release anti-DNA antibodies (106), and subsequently the freed 
antibody can be quantitated in order to estimate amount of complexes 
that were deposited in the tissue. 
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Detection of Immune Complexes in Biological Fluids 
Identification and quantification of immune complexes in biological 
fluids are greatly aided when the specific antigen is known. For in¬ 
stance, radio1abe11ed antibody against the antigen will detect immune 
complexes once free antigen has been excluded. Successful separation 
of free and bound antigens has involved countercurrent Immunoelectro¬ 
phoresis (106). Free and complex-bound antigen can also be differen¬ 
tiated by measuring the amount of antigen that is removed from a biological 
sample when hosts' immunoglobulins are specifically precipitated or 
absorbed. In the case of lactic dehydrogenase virus, the infectivity 
of sera after precipitation of immunog1obu1ins(inc1uding immunoglobulin- 
bound viruses) decreases by an amount proportional to the amount of 
immune complexes (107). 
Assays Involving Physical Properties 
In most cases of immune complex disease, the antigen is not known 
and nonspecific techniques which use physical properties or biological 
activities of immune complexes are necessary. Immune complexes may be 
isolated by size using techniques such as ultracentrifugation with 
sucrose density gradients (108), gel chromatography (109), and ultra¬ 
filtration. The solubility of immune complexes is another property that 
distinguishes them from unbound immunoglobulins. Immune complexes often 
undergo cryoprecipi tat ion, spontaneous precipitation at 0-4°C, and they 
can be differentiated from cryofibrins which are insoluble in acetate 
buffer unlike cryoglobulins. Polyethylene glycol (PEG), an uncharged 
linear polymer, will decrease solubility and thus will precipitate 
proteins depending on the molecular weight of the protein and the con- 
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centration of PEG (110). A k% solution of PEG (MW = 6000) will precipi¬ 
tate immune complexes but not free immunoglobulins (75)- These methods 
are good for analytical study of immune complex disease especially in 
detecting low affinity antigen-antibody reactions which are otherwise 
difficult to study (108), but they are of limited value in routine work. 
Assays Involving Biological Properties 
Biological assays make use of immune complex binding to complement 
receptors, Fc receptors or to other substances specific for immune 
complexes, i.e. bovine conglutinin and rheumatoid factor (RF). These 
assays are fast and well suited for studying immune complexes in many 
patient samples. The major drawbacks to these assays are the difficulty 
in standardizing the assays, especially assays involving the function of 
living cells, and the interference from other biologically active factors. 
Assays Involving Complement Receptors 
Assays involving complement receptors include direct methods to 
detect immune complexes using exogenous Clq binding to receptors in the 
immune complexes or involving complex-bound complement binding to recep¬ 
tors on cells and indirect techniques to demonstrate complement consump¬ 
tion by immune aggregates. Exogenous Clq can be used in direct binding 
or inhibition assays. Both types of Clq assays have broad specificity 
because any serum with immune complexes that bind Clq will have a positive 
test. However, this advantage is offset to a certain extent by the 
nonspecific reactivity of Clq with such substances as C-reactive protein, 
DNA, and endotoxin (111, 112, 113). 
- The Clq agarose precipitation test is a direct binding, but nonquanti- 
tative, test which involves the precipitation of immune complexes with 
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Clq in agarose gel (74). Sera from patients with systemic lupus erythema¬ 
tosus reacts more frequently in this assay than does other pathological 
sera. However, polyanions such as DNA (which is frequently present in 
sera from patients with systemic lupus erythematosus) will bind Clq to 
interfere with this assay and produce false positives (7*0- 
- The 1 2 5 I -C1q binding assay uses PEG to preferentially precipitate 
immune complexes after incubation with radiolabel1ed Clq (75)* The 
addition of EDTA prior to the addition of 12 51 —C1q obviates the need to 
heat inactivate complement in test sera (75)- Furthermore, Clq will 
rarely precipitate with C-reactive protein, endotoxin, or DNA in the 
presence of EDTA (76, 114). 
- The Clq solid phase uses Clq bound to polystyrene tubes prior to the 
addition of test sera. Radiolabeled staph protein A then binds to 
complexes which have bound to Clq (115)* The staph protein A provides 
greater specificity than the previously used radiolabeled antihuman IgG 
provided (115). However, some specificity is sacrificed because staph 
protein A will predominantly bind complexes containing Ig G1, or I g G 2 
(116). 
- There are several Clq inhibition assays in which immune complexes in 
test sera inhibit 12 5 l-C1q from binding to some substance, i.e. sepha- 
rose (117), latex particles (118), or red blood cells (119)- In 
general, these assays are more prone to interference than the direct 
binding assays. 
Complement levels can also be used to evaluate the presence of 
immune complexes indirectly by determining the anticomplementarity of 
the sera using complement fixing (120). Interference in this assay 
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could be caused by alternate pathway activators (endotoxin, C3, nephritic 
factor, enzyme splitting complement component Cl, and plasmin) and 
activators of Cl (C-reactive protein, heparin, and DNA). Low levels of 
complement can provide evidence for immune complexes but a low complement 
profile is not conclusive evidence for immune complexes. Further studies 
of complement breakdown products are necessary to demonstrate complement 
activation in the face of normal or elevated complement levels (121, 122, 
79). 
The Raji cell assay developed by Theofi1opou1 os et al (77) employs 
immune complex-bound complement reacting with the C receptors on the cell 
surface. Raji cells are from a 1ymphob1astoid line of cells which have 
Fc and complement receptors but no surface immunoglobulins (123, 124). 
Immune complexes which bind to the cells are detected using radiolabeled 
anti-human IgG with enough excess to flood the Fc receptors {11). There¬ 
fore, differences in radioactivity on Raji cells incubated with pathologic 
versus control sera will correspond to the presence of immune complexes 
(77). Like the Clq assays, the Raji cell assay detects complexes that 
bind complement (those with IgG, IgM and possibly IgA). Monomeric IgG 
also binds to Raji cells to potentially cause false positives, but the 
high ratio of complement receptors to Fc receptors and the standardization 
of IgG in patient samples probably minimizes this source of error {11). 
High levels of complement components C3d and C3 may displace complexes 
from the cells, and low complement levels may cause false negatives. 
Finally, the presence of anti1ymphocyte antibodies may result in false 
positives. 
Assays Involving Fc Receptors 
Immune complex assays which involve binding to the Fc receptor on 
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cells potentially have high sensitivity but no successful method for 
measuring direct Fc receptor binding has been reported. Consequently, 
immune complex assays involving binding to the Fc receptors all require 
the measurement of active cellular function stimulated or inhibited by 
immune complexes. Therefore, the assays must include standardization 
for cell metabolism as well as other parameters. Although complexes have 
a greater affinity for cell Fc receptors, uncomplexed immunoglobulins 
will bind on the receptors making standardization of immunoglobulin con¬ 
centration in test sera necessary. 
- In the platelet aggregation test (PAT) dilutions of test sera are used 
to aggregate platelets on microtiter plate (125). Interference is caused 
by platelet surface antibody, polyanions, and proteolytic enzymes, and 
some myxoviruses (126). 
- In the K cell cytotoxicity assay blood lymphocytes are incubated with 
51Cr labeled target cells sensitized with rabbit antibody (127). Cell 
lysis and release of 51Cr are inhibited by immune complexes but also to 
some extent by uncomplexed serum immunoglobulins and anti1ymphocyte anti¬ 
bod ies (127). 
- In the macrophage inhibition assay peritoneal exudate cells are incu¬ 
bated with test sera and radiolabeled aggregated IgG (128). Immune 
complexes in test sera will inhibit phagocytosis of the radiolabeled 
aggregates. The presence of anti-IgG might enhance phagocytosis and 
induce error in this assay (128). 
Assays Involving Rheumatoid Factor or Bovine Conglutinin 
Rheumatoid factor (RF) and bovine conglutinin are both substances 
with specificity for immune complexes that do not involve binding via 
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the usual complement or Fc receptor. Rheumatoid factor can either be 
of the IgG type or IgM type anti-igG. Bovine conglutinin is a high 
molecular weight protein that binds immune complexes with fixed comple¬ 
ment, especially C3d (129). 
The RF assays are all inhibition assays using mRF or pRF except 
for the direct precipitation of RF and immune complexes in agarose gel 
(55)- The selection of RF is very important because RF binding depends 
on the patient it was obtained from, and it is necessary to study a 
number of patients to find a RF with the greatest specificity and sensi¬ 
tivity. Monoclonal RF (mRF) obtained from patients with 1ymphoprolifera- 
tive disease is generally more efficient than polyclonal RF (pRF) (55). 
Using the RF assays, positive results were observed in a majority of 
sera from patients with rheumatoid arthritis (57) but not patients with 
other diseases, i.e. systemic lupus erythematosus (55)- 
- In the assay developed by Luthra et al (57)» immune complexes in test 
sera inhibit mRF conjugated to microcrystalline cellulose from binding 
to radiolabeled aggregated immunoglobulins. 
- In the mRF assay developed by Lurhuma et al (129), immune complexes 
inhibit mRF aggregation of latex particles coated with IgG. One limita¬ 
tion is the fact that the presence of anti-igG in test sera may mask the 
detection of the complexes. In addition to heat inactivating test sera 
prior to the assay, the assay must also be standardized for the concentra¬ 
tion of IgG in the test sera because monomeric IgG can compete with 
complexes for the binding sites on RF (129). 
- In the mRF assay by Gabriel et al (68), immune complexes inhibit 125l 
mRF from binding to sepharose. This assay avoids interference by poly- 
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clonal factors in patient sera. 
- In the pRF assay by Crowdery et al (130), immune complexes inhibit 
pRF from binding to radiolabeled aggregated IgG which is then precipi¬ 
tated by antihuman IgM. The presence of anti-IgG in test sera may 
cause interference in this assay. 
The bovine conglutinin assay involves incubation of radiolabeled 
aggregated IgG and test sera in polypropylene tubes coated with conglutin¬ 
in (131)- Immune complexes in the test sera will inhibit conglutinin 
binding to the labeled aggregates. This assay has many false negatives 
which may be due to insufficient complement in some test sera. 
The ideal antigen-nonspecific assay would be specific, sensitive, 
and simple. The specificity is often difficult to access since all 
assays will give false positives with aggregated IgG. To ensure against 
this error, heating sera over lt8°C and unnecessary freezing and thawing 
should be avoided. Evidence of assay specificity for immune complexes 
can be obtained by standardizing the assay against aggregated IgG, by 
comparing the assay results from patients with known disease with the 
results from controls, and by analyzing the size of the material identi¬ 
fied in the assay -- immune complexes are larger than monomeric IgG. 
The sensitivities of various assays are difficult to compare because 
few descriptions of assays report the size of IgG aggregates used in the 
standardization. The Raji cell assay, for instance, has greater sensi¬ 
tivity for large complexes formed near the equivalence point (77)- On 
the other hand, some assays have greater sensitivity for a particular 
type of complex, i.e. the mRF assay for complexes found in rheumatoid 
arthritis (57)- At the present time immune complex assays cannot be con¬ 
sidered quantitative and their sensitivities must be based on their 
ability to correlate with clinical disease. 
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I I. METHODS AND MATERIALS 
Patient Selection, Sera Collection, Storage of Sera 
The C1q reactivity of 46 sera and 10 joint fluids from 30 patients 
-- between the ages of three and 67 years -- was demonstrated using the 
1 2 51 -C1q binding assay. The diagnosis of Lyme arthritis was based on 
patients having the unique skin lesion of ECM, typical attacks of oligo¬ 
arthritis, and residency in the endemic area. Patients were evaluated 
for signs and symptoms at each clinic visit and placed in one of the 
following categories [1] Skin: patients with only ECM. [2] Joints: 
patients with arthritis, ECM still present or not, but no other systems 
involved. [3] Heart: patients with cardiac conduction abnormalities, 
regardless of ECM, arthritis, or peripheral neuropathy. [4] Centra1 
Nervous System: patients with meningitis or meningoencephalitis (docu¬ 
mented by abnormal cerebrospinal fluid), regardless of all other features. 
[5] Peripheral Nervous System: patients with a peripheral neuropathy, 
without central nervous system or heart involvement, and regardless of 
skin or joint involvement. [6] Remission: patients with no symptoms or 
signs for at least two weeks. In order to define the relationship of 
immune complexes to the clincal course of Lyme arthritis, an additional 
23 and 11 sera samples were obtained from two chronically ill patients, 
an 8-year-old boy and a 36-year-old woman respectively. 
At each clinic visit, blood to be tested for immune complexes was 
drawn in Vacutainer tubes (Becten, Dickinson and Co., Rutherford, New 
Jersey) and allowed to clot for 1 hr. at 25°C. After centrifugation 
the serum was collected, stored in aliquots at -70°C in polypropylene 
vials (Electro Sonic Co., Hawthorne, California) and thawed a single 
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time for assay. The serum was stored a maximum of ten months prior to 
assay. 
Isolation of C1q 
Clq was isolated by the method of Yonemasu and Stroud (132). 
Day 1: Blood from fasting donors was allowed to clot at 25°C for 1 
hour and then stored for 1 hour at 4°C for clot retraction. Serum was 
separated by centrifugation at 1000 X g for 30 minutes at 4°C. About 
100 ml of serum was combined with 25 ml of 0.1M disodiurn ethylene diamine 
tetraacetic acid (EDTA; pH 7-5) and incubated for 10 minutes at 37°C. 
The solution was cooled to room temperature and adjusted to pH 7-5 using 
NaOH and to a relative salt concentration (RSC) of 0.040 by titrating 
with 0.005M EDTA (pH 7-5)- The solution was incubated with stirring for 
1 hour at 4°C. After centrifugation at 10,000 X g (Servall centrifuge 
with GSA rotor) for 30 minutes and removal of the supernatent, the 
precipitate was washed twice with 0.1M EDTA buffer (pH 7-5, RSC = 0.0k) 
using twice the original volume of the serum. The precipitate was dis¬ 
solved in 12 ml of 0.01M EDTA buffer (0.75M NaCl, pH 5-0). 
Day 2: The mixture was centrifuged at 25,000 X g for 30 minutes. The 
supernatent was collected, placed in dialysis tubing with a permeability 
of 24 Angstrom (VWR Scientific Co.) and dialysed overnight against 2 
litres of 0.1M EDTA (pH 5-0, RSC = 0.078) at 4°C. 
Day 3• The dialysing buffer was changed for 2 litres of fresh buffer, 
and dialysis was continued for 3 hours. Contents of tubing were collect¬ 
ed and centrifuged at 10,000 X g for 30 minutes at 4°C. The supernatent 
was discarded and the precipitate was washed twice with 0.01M EDTA 
(pH 5-0, RSC = 0.078). The precipitate was redissolved in 0.005M EDTA 
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(pH 7-5, 0.3M NaCl) and refrigerated overnight. 
Day 4: After the mixture was centrifuged at 20,000 X g for 30 minutes 
in the cold, the supernatent containing purified Clq was collected and 
stored at ~70°C until used. The isolated Clq readily agglutinated 
latex particles coated with aggregated IgG but did not react with anti¬ 
sera to IgG, IgA or IgM in double diffusion in 1% (wt/vol) agarose gels. 
Labeling Clq 
Two hundred yg of isolated Clq was radiolabeled with 125l (New 
England Nuclear Corp., Cambridge, Mass.) by a modification of the lacto- 
peroxidase technique (133)- First the Clq solution was dialyzed in 
phosphate buffered saline (PBS; pH 7•4, 0.01M P04, 0.15M NaCl) overnight. 
To 100 ml of mixture (protein concentration 1 mg/ml), 6 yl of lactoper- 
oxidase (protein concentration 1 mg/ml) was added. A 0.1M solution of 
potassium iodide was diluted 1:5000 in PBS and then added to the reaction 
mixture. 
Under a hood 1251 (100 mCi/ml) was diluted five-fold in PBS, and 
10 yl of diluted 1251 (a total of 200 mCi) was added to the above mixture 
containing Clq, 1actoperoxidase and K1. The reaction was started by 
adding 10 yl of H202(l:000 dilution of 30% H202 in PBS). After incubating 
for 20 minutes the reaction mixture was stopped with 1 ml of PBS. The 
mixture was dialysed for 4 hours against veronal buffer solution (VBS, 
.02M Na barbital, 0.25mM CaCl2, .75mM MgCl2, pH 7-3). The VBS was 
replaced with fresh buffer and the dialysis continued overnight. The 
1 2 51 — C1q had a specific activity of 0.6 to 0.9 mCi/yg of protein; and 
10 yg aliquots were stored in 100 ml of VBS at -70°C. Prior to each 
assay, an aliquot was thawed, diluted to 5 ml with VBS containing 1% 
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bovine serum albumin (A grade Cal biochem, San Diego, California) and 
centrifuged at 20,000 X g for AO minutes to remove aggregated protein. 
The 12 51-C1q Binding Assay 
The assay was performed in triplicate as described by Zubler et 
a 1 (56). 
Serum: For each test, 50 yl of unheated serum was combined with 100 
yl of 0.2M EDTA (pH 7-5 adjusted with NaOH) in Bio Vial polypropylene 
tubes (Beckman Instruments, Inc., Palo Alto, California). The mixture 
was transferred to an ice bath, and 50 yl of 12 51 -C1q solution was added 
immediately by 1 ml of 3% (wt./vol.) polyethylene glycol (PEG; Fisher, 
Pittsburgh, Penn.) in borate buffer (0.1M boric acid, 0.25 M di-sodium 
tetraborate, 0.075M NaCl, pH 8.3). After the addition of PEG, the mix¬ 
ture was incubated for 60 minutes at 4°C and then centrifuged in the 
cold for 20 minutes at 1,300 g. Under these conditions, Clq binds to 
the immune complexes while unbound Clq remains in solution. Precipitated 
radioactivity was determined in an automated gamma spectometer (Biogamma 
^00, Beckman Instruments, Palo Alto, California). The precision and 
reproducibility of this method were tested using positive control serum 
from a patient with rheumatoid vasculitis and cryoglobulinemia. The 
coefficient of variation was k% among 10 aliquots tested on the same 
day, and 11% among 7 aliquots tested on separate days. 
Synovia 1 Fluid: Synovial fluids, collected in tubes containing EDTA 
(final concentration 20 mM) were tested in the same manner but were 
diluted 1:2 in NHS prior to testing. When tested in this manner, Clq 
binding in synovial fluid from patients with osteoarthritis was not 
significantly different from NHS. 
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Sucrose Density Gradient Ultracentrifugation 
The relative molecular size of the Clq reactive material was 
determined by fractionating sera on 10-40% linear sucrose density 
gradients in PBS (pH 7-4) using a Spinco model 65~75 ultracentrifuge 
with a SW 50.1 Ti rotor. Test samples were diluted 1:3 with PBS and 
200 yl aliquots were applied to 4.5 ml gradients and sedimented at 
192,000 g for 14 hours. Individual 0.25 ml fractions were then collected 
from the bottom of each tube and analyzed for immune complexes. The 
location of IgG (7S marker) and IgM(19S marker) was determined by double 
diffusion in 1% (wt./vol.) agar gel. 
Analysis of Results 
Clq reactivity of sera and joint fluid from patients with Lyme 
arthritis was compared directly with sera from normal donors. Three of 
the 50 (6%) sera from normal donors surveyed with the 12 51 -C1q binding 
assay had Clq reactivity 2 to 6 standard diviations from the mean. 
These sera were presumed to have excess reactive material -- immune 
complexes -- and therefore excluded. The remaining sera had reactivity 
approximating a Gaussian distribution (figure #1). The range of Clq 
binding in a panel of 10 normal sera was determined at each assay. 
Pathological sera with Clq binding greater than two S.D. from the mean 
of normal human sera (NHS) were considered to contain immune complexes. 
Measurement of Complement 
The complement determinations were performed in the laboratory of 
Dr. S. Ruddy. Total hemocytic complement (CH50) was measured by the 
method of Kent and Fife (134) and the third (C3) and fourth (C4) com¬ 
ponents by radial immunodiffusion in Hyland Plates (Hyland, Div. Travenol 
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Labs., Inc., Costa Mesa, California). 
Measurement of Cryolgobulins 
Blood for cryoglobulin determination was clotted at 37°C for one 
hour. The serum was collected by centrifugation at kOO X g for 20 
minutes, and then 5 ml was allowed to stand for 72 hours at 4°C. Any 
precipitate that formed was sedimented at 1000 X g for 20 minutes in 
the cold, washed three times with cold PBS (pH 7-^, 0.01M PO4, 0.15M 
NaCl), and resuspended in 0.5 ml PBS at 37°C. The total protein was 
measured by the method of Lowery et al (135)- 

FIGURE #1 
125 
l-Clq BINDING OF NORMAL SERA 
counts per minute 
(x 100) 
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III. RESULTS 
Standardization of the 12 5 I~C1q Binding Assay 
Aggregates of IgG were formed by dissolving lysophilized IgG in 
phosphate buffered saline (PBS; pH 7-4) and heating the solution at 63°C 
for twenty minutes. The solutions with aggregated IgG were then diluted 
1:3 in normal human serum. The standard curve (figure #2) shows a 
linear relationship between the concentration of the aggregated IgG and 
the reactivity of the sample. This relationship remains linear down to 
a concentration of 120 yg/ml of the aggregates. In the 50 yl aliquot 
of serum that is used for the assay, a minimum of about 2 yg is reactive 
in the assay. This sensitivity agrees with other reports of the Clq bind¬ 
ing assay sensitivity (56) and with reports of the sensitivities of 
other assays, i.e. the Raji cell assay (77), and the rheumatoid factor 
inhibition assay (1 17) - 
Measurement of Immune Complexes 
I measured immune complexes in 44 sera from 30 patients with Lyme 
arthritis using the 125 I -C1q binding assay (table #1). Among sera from 
patients with active disease 26/37 {10%) gave positive reactions. In 
contrast only 1/7 (14%) sera from patients in remission was positive 
in the assay. Only 9/14 (64%) of patients with arthritis had positive 
results in the assay (table #2). However, patients with extra-articular 
symptoms were frequently positive. Patients with ECM nearly always 
(10/11, 91%) had positive results in the assay, and both patients with 
nervous system involvement had positive results in the assay. The sickest 
patients, those with nervous system involvement, had sera with the greatest 
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Clq reactivity. Two or more sequential samples were obtained from 7 
patients over a period of up to 8 months. These samples tended to remain 
either consistently positive or negative in the 12 51 -C1q binding assay. 
All 11 of the synovial fluids from 10 patients with Lyme arthritis 
were positive in the 12 51 — C1q binding assay (table #3). However, only 
6/11 of the sera samples obtained from these patients were positive in 
the assay. 
Measurement of Complement 
Complement levels were tested by measuring CH50, C3, and C4 in 
15, 30, and 26 of 44 sera respectively (figure #3)« Levels of CH50 
were normal or elevated, and the levels of C3 and C4 were each below 
normal on only three occasions. Many patients, particularly those with 
arthritis, had complement levels above normal. In general, complement 
levels did not correlate with the 12 51 -C1q reactivity of sera. 
Physiochemica1 Properties of Immune Complexes 
Analysis of complex size on sucrose density gradients demonstrated 
a correlation between complex size and disease manifestations. Sera 
from patients with early mild disease (ECM alone) and those from patients 
with more severe disease were fractioned and tested by the 1^51 -C1q 
binding assay (figure #4). Complexes of 7S and 19S size were present 
in both patient groups but patients with severe disease had a predomi¬ 
nance of the 19S complex while those with mild disease did not. The 
presence of 1251 -C1q reactivity with a substance of 7S size was difficult 
to account for because that size corresponded to a single IgG or a small 
antigen-a size which would be too small to fix complement (136). However, 
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FIGURE #2 
125 I-C 1 q BINDING OF AGGREGATED IgG 
counts 
per 
minute 
( xlOO) 

TABLE H\ 
4A 
COMPARISON OF Clq BINDING AND COMPLEMENT LEVELS 
IN PATIENTS KITH LYME ARTHRITIS 
Intervals 
Clinica1 
Activity Pt. 
Between 125 
Sequential I-Clq 
Samples (Mos.) Binding* CH50 C3 CA 
(units) (pg/ml) (Pg/ml) 
Skin A 2.3 ND 12 TT “TTZTT 
B A.2 ND 89 ND 
C 3.3 ND ND ND 
D 6.9 ND ND ND 
E 8.7 ND ND ND 
F 3.7 ND ND ND 
C 3.3 ND ND ND 
H A.9 ND 89 ND 
1 2.8 ND ND ND 
J - ND ND ND 
K 2.0 ND ND ND 
Joints L A. 1 ND 281A A31 
M 2.8 21A 1252 163 
II 1 5.5 258 163A 21A 
N 2.3 ND 2306 267 
0 2,A ND 2383 A6A 
II 
>- ND ND ND 
P - 207 1125 177 
II 1 A.6 ND ND ND 
Q 2.5 A07 2232 630 
R - ND 1997 AA5 
S 2.0 30A 2232 543 
T 3A1 3031 5A3 
U 2.1 335 2323 261 
V - 338 1270 ND 
It 8.5 ND 183A 303 
II 0.25 ND ND ND 
W - ND ND ND 
X 2.0 31A 3231 550 
Y 2.0 ND 80 ND 
II 3.5 ND ND ND 
Centra 1 z 15.A 171 15A3 300 
Nervous II 2 15.8 153 1900 261 
System II 2 6.9 236 761 290 
II 3 7.7 ND 798 240 
- . - - - _ 
AA 
_ 6.0 
_ I?3 ND _ND _ 
Heart R 
- 
ND 1997 AA5 
Remission BB 175 2015 471 
CC 175 1651 308 
u ND 2338 238 
II A 259 1706 177 
DD ND 1 72A 261 
EE ND 1300 230 
FF 2?6 ND ND ND 
*S.D. above mean of normal controls 
(-) denotes results within the range of normal 
[Complement values were determined in the laboratory of 
Dr. S. Ruddy] 
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TABLE n 
Clq Reactive material During Different Phases of the Illness 
Latter Attacks 
ECM-': Nervous System Joints Remission 
Patients Tested 
Number Positive (%) 
1 1 
10 (91%) 
2 
2 (100%) 
14 
(9) (64%) 
7 
1 (14%) 
*Within three weeks of onset 

TABLE #3 
Clq Binding* in Serum and Synov ia 1 Fluid 
Patient Se rum 
Synovia 1 
Fluid 
A NL 8.6 
B NL 9.6 
C NL 6.4 
D 6. A 4.9 
E 
oo
 
P
O
 
5.6 
F 1.5 3.7 
G NL 7.9 
H 3.1 2.2 
1 1 4.5 6.6 
1 5.0 20.0 
J 8.1 6.0 
Total 1 1 1 1 
Numbe r 
Positive(%) 7 (64%) 11 (100%) 
'-’-'Results are expressed as S.D. 
mean of normal sera. 
above the 
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SERUM COMPLEMENT LEVELS 
CH50 
CIC CIC 
(+) (-) 
C3 C4 
CIC 
(+) 
CIC 
(-) 
CIC 
(+) 
CIC 
(-) 
CIC = circulating immune complexes 
-complement values were determined in the 
laboratory of Dr. S. Ruddy- 
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FIGURE #4 
125 I - Clq BINDING 
Patients with PCM Patients with Systemic 
Complication 
19 S PATIENT M 
J I I I I L 
PATIENT M 
3 5 7 9 II 13 
FRACTION NUMBER 
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the 7S materia] was not present in normal sera, and Clq reactive material 
of 7S density has been demonstrated in the sera of patients with systemic 
lupus erythematosus (56). 
Some serum cryoglobulins from Lyme arthritis patients contained 
1 2 51 —C1q reactive material (table #k). Blood from six patients with 
Lyme arthritis and cryoglobulins was allowed to clot at 37°C for 30 
minutes. The serum was removed and an aliquot was tested for 12 51 - C1q 
reactivity. Cryoglobulins were precipitated by storing the sera at 4°C 
for 2k hours. The cryoprecipitab 1e proteins were removed by centrifuga¬ 
tion and then redissolved in a starting volume of normal serum. Both 
the supernatent (serum minus cryoglobulins) and the redissolved cryopre- 
cipitate were tested. Five of the six sera had a decrease in Clq 
reactivity. The three sera with the most Clq reactivity transferred the 
reactivity to normal sera. 
Patient Studies 
I investigated the relationship of circulating immune complexes to 
the course of Lyme arthritis by following two patients for about nine 
months during various phases of their illness using the 1 2 5 I-C1 q binding 
assay (figures #5, 6). The extent of 12 5 I -C1q binding activity tended 
to parallel the clinical course of these patients. One patient, an 
eight year old boy who was the sickest of the patients tested, illustrated 
the correlation between Clq reactivity and disease activity. 
His initial clinic visit was July 1976 when he presented with an 
expanding skin lesion, headache, stiff neck and vomiting. Serum analy¬ 
sis revealed cryoglobulins composed of IgM with normal complement levels. 
ECM faded though mild symptoms persisted over the next month. On 26 

TABLE #4 
50 
Clq Reactivity* of Cryoglobulins from Patients with Lyme Arthritis 
Patient Serum Normal Serum+ 
Pa tient Whole 
Minus Cryo¬ 
globulins 
Plus Redissolved 
Cryoglobulins 
1 7.8 2.4 2.5 
2 7.7 6.7 3.2 
3 5.6 1.6 3.3 
4 2.5 1.4 .4 
5 2.1 2.7 .4 
6 2.0 1.5 .6 
125 
* I-Clq binding assay, expressed as S.D. above the mean of 
norma 1 sera. 
+Clq reactivity 0.4 S.D. 
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FIGURE #5 
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August the patient had his worst fever in addition to headache, stiff 
neck and left shoulder pain. Serum cryoglobulins contained IgM and IgG 
with low normal complement levels. Oral prednisone was begun and the 
symptoms improved. 
Beginning on 10 September he had serum samples analyzed in the 
125l-Clq binding assay (figure #5)* In September and October he had 
moderate exacerbations of symptoms -- including fevers, joint pain, 
and adenopathy -- which correlated with peaks of Clq reactivity. Symp¬ 
toms of only mild adenopathy and occasional headaches in November were 
accompanied by declining Clq reactivity of serum. In mid-December he 
developed choreiform movement of his hands with electroencephalogram 
changes followed by a sudden onset of pain and swelling in his right knee. 
These symptoms correlated with another peak of Clq reactivity of his 
serum. These acute symptoms resolved but the patient was left with a 
persistent arthritis -- diminishing over the next several months. A 
peak in Clq reactivity preceded the reappearance of the skin lesion in 
February and coincided with the onset of fever in March. The patient 
clinically improved and had no further peaks of Clq reactivity of serum, 
and by May he was nearly asymptomatic although his tests for 12 b1 -C1q 
binding activity were still positive. 

IV. DISCUSSION 
Lyme arthritis is a new disease of undetermined etiology. Although 
this disease was initially misdiagnosed as rheumatoid arthritis or juven¬ 
ile rheumatoid arthritis, it has several clinical and laboratory features 
which are now recognized that set it apart from these disorders. Twenty- 
five percent of Lyme arthritis patients do satisfy the American 
Rheumatism Association's definition of juvenile rheumatoid arthritis 
(1) which is 6 weeks of monoarticular arthritis or polyarticular arthritis 
if other symptoms (i.e. fever, rash, or morning stiffness) are present 
or 3 months of arthritis if other symptoms are absent (137)* However, 
the seasonal onset and the geographical clustering of Lyme arthritis 
distinguish this disease from juvenile rheumatoid arthritis. Unlike 
rheumatoid arthritis, Lyme arthritis is usually asymmetric and affects 
mostly large joints. In addition, antinuclear antibodies, rheumatoid 
factors or rheumatoid nodules have not been observed in Lyme arthritis. 
Two patients with Lyme arthritis developed carditis and fulfilled the 
Jone's criteria for acute rheumatic fever. However, in those two patients, 
the diagnosis of rheumatic fever could be excluded because of the lack 
of prior streptococcal infection detectable even by rising plus anti- 
streptococcal antibody titers, the presence of ECM as opposed to erythema 
marginatum, and the lack of significant response to aspirin (2). 
Several clinical and laboratory features suggest that immune com¬ 
plexes are present in Lyme arthritis. The short attacks of arthritis, 
peripheral neuropathies, cardiac conduction defects and involvement of 
the central nervous system resembles known immune complex diseases such 
as serum sickness. Moreover, some patients have cryoglobulins in their 
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sera. As demonstrated by Steere et al (1) patients with ECM and cryo¬ 
globulins are more likely to go on to develop arthritis. 
I have demonstrated that the sera and synovial fluids from patients 
with Lyme arthritis often react positively in the 12 5 I —C1q binding assay. 
The reactive material sedimented at 19S -- a density consistent with 
immune complexes involving polyvalent antigens. Further verification 
of the assay specificity for immune complexes was obtained by testing 
the reactivity of normal human sera with and without the addition of 
aggregated human IgG (agg. IgG). Only three of the 50 (figure #1) nor¬ 
mal sera reacted in the assay whereas sera with IgG aggregates reacted 
in the assay with a linear relationship between the concentration of 
agg. IgG and the reactivity of the sample. A minimum of about 2 yg 
in the assay aliquot was reactive. Zubler et al (56) reported a similar 
sensitivity of the 125 I-C1 q binding assay using agg. IgG and complexes 
composed of human IgG and rabbit anti-human antibody. 
Furthermore, the Clq reactive material was disease related. Though 
reactive material was hardly ever present in normal sera, 27 of A4 sera 
from Lyme arthritis patients reacted positively in the assay. This 
reactive material was frequently present in the sera of patients with 
active disease 26/37 but rarely in patients with inactive disease 1/7- 
The sickest patients, those with central nervous system involvement, 
had the greatest amounts of reactive material in their sera. Patients 
with systemic involvement, i.e. ECM or nervous system involvement, more 
frequently had sera with positive tests than did sera from patients with 
symptoms localized to the joints. Similarly in rheumatoid arthritis, 
Zubler et al (56) reported that patients with systemic symptoms more 
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frequently had positive results in the 1 2 51 — C1q binding assay than 
patients with arthritis alone. A longitudinal study of two patients 
with Lyme arthritis revealed that the Clq reactivity of sera rose and 
fell in parallel with exacerbations and remissions of disease. Changes 
in serum Clq reactivity in those two patients correlated best with 
changes in systemic rather than joint symptomatology. 
Synovial fluids from Lyme arthritis patients also contained Clq 
reactive material while synovial fluids from patients with osteoarthritis 
did not. The synovial fluids reacted positively in the assay significant¬ 
ly more frequently 11/11 than did sera from the same patients 7/11- 
This observation was similar to the report by Zubler et al (56) that 
synovial fluids from rheumatoid arthritis patients were more frequently 
positive in the 12 5 I -C1q binding assay than were the sera samples. An 
explanation of this discrepancy between the Clq reactivity of serum and 
synovial fluid has been provided by Nydegger et al (63) with the demon¬ 
stration that complement breakdown product, C3d, levels in serum and 
synovial fluids did not correlate. These results were consistent with 
parallel activation of complement in serum and synovial fluid and there¬ 
fore parallel production of immune complexes. Consequently, patients 
with arthritis alone -- either because antigen production, antibody pro¬ 
duction, or both were localized to synovial tissues -- would not be expected 
to have marked elevations of serum immune complexes. 
In short, 1 found that sera from Lyme arthritis patients with systemic 
disease frequently reacted and synovial fluids from patients with arthri¬ 
tis always reacted in the 12 5 I -C1q binding assay. These correlations 
between clinical features of Lyme arthritis and reactive material in 
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the sera and synovial fluids indicate that reliable measurements of 
disease-re 1 a ted substance, most likely immune complexes, were being 
made. 
In a cooperative study with our laboratory; Hardin, Walker et al 
(138) confirmed the presence of reactive material in the sera of 
patients with Lyme arthritis using two other assays for immune complexes, 
the Raji cell assay and the Clq solid phase assay. The 12 5 I - C1 q binding 
assay and the Clq solid phase results were usually concordant, and 
regression analysis demonstrated a strong positive correlation between 
the numerical values of the two assays. Furthermore, reactive material 
in the Clq solid phase assay also sedimented at 19S. In contrast, no 
correlation existed between the results of the Raji cell assay and 
either of the other two assays. Fewer sera had positive results in the 
Raji cell assay even though four sera were reactive in this assay alone. 
Similar discrepancies between the Clq solid phase and the Raji cell assay 
have been demonstrated in patients with gonococcemia (115) and glomeru- 
lonephritis (139)- 
The three assays all depend on the ability of immune complexes to 
fix complement, but differences in assay design may cause certain immune 
complexes to be preferentially detected in,and certain interfering fac¬ 
tors to primarily affect,one assay. The 125 I-C1q binding assay will 
theoretically detect immune comp 1exes consisting of any immunog1obu1 ins 
which will bind complement and immune complexes of both large and small 
size. But this assay has less specificity with possible interference 
from C-reactive protein, DNA and endotoxin (111, 112, 113)- The Clq 
solid phase assay is theoretically the most specific of the assays 
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because only complexes which bind Clq and staph protein A -- those with 
IgGl or IgG2 -- will react in this assay (116). However, immune com¬ 
plexes with IgM, 1gG3, or IgA may not be detected. 
Part of the discrepancy between the results from the two Clq assays 
and the Raji cell assay may be explained by the differences in principle 
between them. The Raji cell assay detects complexes with bound C3 via 
cell surface complement receptors (140), whereas the Clq assays detect 
immune complexes that bind exogenous Clq (75> 139). Larger immune com¬ 
plexes formed near the equivalence point are preferentially detected in 
the Raji cell assay, and the assay is subject to a variety of interfer¬ 
ences (77). Monomeric IgG and warm-reactive anti1ymphocyte antibodies 
might bind to these cells to cause false positives. In addition, the 
variations in complement levels may lead to erroneous results. Elevated 
levels of serum C3 may displace the cell-binding component of complement, 
C3b, from the cells. On the other hand, immune complexes in complement 
depleted sera may fail to react to the Raji cell assay. 
The two Clq assays detected reactive material in about ^5% of the 
sera from patients with active disease, and there was a remarkable 
correlation between the two assays (p <.001). These observations pro¬ 
vided further evidence that immune complexes were present in patient 
sera, and possibly the results actually underestimated the true incidence 
of circulating immune complexes. The sera in the study had clotted at 
25°C, a temperature at which some cryoprecipitable immune complexes 
become insoluble (141). Though the period of sera collection was short 
(about half an hour) and the temperature was well above b°C, some Clq 
material may have been lost. 
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Many additional laboratory features suggest that immune complexes 
are involved in the pathogenesis of Lyme arthritis. For example, cer¬ 
tain patients with Lyme arthritis have serum cryoglobulins which contain 
Clq reactive material (table #4). Patients with cryoglobulins have 
been noted to have depressed levels of complement consistent with con¬ 
sumption by immune aggregates (2). 
The Clq reactive materials had compositions and densities consistent 
with those of immune complexes. The complexes were composed of IgG1 or 
lgG2 and complement to react in the Clq solid phase and Raji cell assays. 
Serum from Lyme arthritis patients had Clq reactive material in the 
lower and top portions of sucrose density gradients indicating the pre¬ 
sence of reactive substances with 19S and 7S densities respectively. 
Similar 19S reactive substances have been reported in rheumatoid arthri¬ 
tis (56) and cytomegalovirus infections (142). Immune complexes of this 
size are likely to cause tissue injury (143), and it may be important that 
the largest amounts of this reactive material were detected in patients 
with severe clinical manifestations. The high density material was 
detected best in the Clq assays', thus it is not surprising that sera 
from patients with active disease were more frequently positive in the 
Clq solid phase and the 12 51 -C1q binding assays than in the Raji cell 
assay. 
The low density material was consistently reactive in the 125 I -C1q 
binding and Raji cell assays when patient sera was tested but not when 
normal sera was tested. Furthermore, sera from patients with systemic 
lupus erythematosus had Clq reactive material of 7S density in the 
12 5 I-C1q binding assay (56). The relatively greater reactivity of this 
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material in the Raji cell assay might be explained by the presence of 
immune complexes with complement receptors already saturated or by 
the presence of anti1ymphocyte antibodies. The reactivity of the 7S 
material in the 1 2 51 -C1q binding assay might be the result of anti¬ 
bodies directed against Clq. Low density complexes composed of small 
antigens and IgG or IgG alone might undergo sufficient conformational 
change with subsequent increase in density in order to precipitate 
after Clq binding and the addition of PEG. Anti1ymphocyte anti¬ 
bodies circulating as complexes with cell surface antigens might explain 
the reactivity of low density material in both the Raji cell and the 
12 51 -C1q binding assay. Winfield et al (1A4) have reported the presence 
of anti1ymphocyte antibodies in the serum cryoprecipitate of patients 
with systemic lupus erythematosus. Of the four patient sera that were 
fractionated and tested by the Clq solid phase assay, only two had 
reactive material of 7S density. The decreased reactivity of this 
material in the Clq solid phase assay might have resulted from the 
presence of complexes which only weakly bind staph protein A, i.e. com¬ 
plexes composed predominantly of IgG3- 
The sera with reactive material did not appear to have depressed 
complement levels (figure #3) which usually follow the production of 
complexes unless there is increased synthesis of complement. In rheu¬ 
matoid arthritis, for example, the complement levels are usually normal 
or elevated (59, 60, 61), yet Nydegger has demonstrated that the acti¬ 
vated component of complement, C3d, was elevated in parallel with the 
125 | — C1q binding activity (63). Patients with ECM and cryoglobulins 
have been noted to have depressed levels of complement (2). This 
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discrepancy between the normal complement levels in the presence of 
Clq reactive material and the depressed complement levels in the pre¬ 
sence of cryoglobulins might be explained by a qualitative difference 
between the two substances. This difference was demonstrated by the 
fact that not all cryoglobulins transferred Clq reactivity (table fth) 
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V. SUMMARY 
Immune complexes are present in a number of disorders where they 
are thought to be of pathogenetic importance. To this group can now 
be added Lyme arthritis, a newly recognized, cyclical, inflammatory 
disease thought to be transmitted by an arthropod vector. The disease 
affects predominantly skin and joints and to a lesser degree the nervous 
system and heart. Tests for antinuclear and rheumatoid factors have 
been negative, but some patients have serum cryoglobulins. Consequently, 
I looked for circulating immune complexes using the 1251 -C1q binding 
assay. 
I tested kk sera from 3& patients who had either active disease or 
a recent remission. Almost all the positive reactions occurred in the 
sera from patients with active disease 26/37 (70%) versus 1/7 (1^%) 
with inactive disease. In addition the synovial fluids from 10 patients 
were all positive. 
The densities of the complexes were determined by fractionating six 
sera from five patients on sucrose density gradients and analyzing them 
in the 12 51 - C1q binding assay. This method demonstrated Clq reactive 
material of 19S and 7S densities. The larger 19S material predominated 
in patients with severe disease, and similar size complexes have been 
reported in other immune complex diseases (1^2). The identity of the 
7S material and its relation to disease activity has not yet been deter- 
mined. 
This thesis demonstrates that patients with Lyme arthritis have 
circulating immune complexes. Their relationship to active disease and 
their physiochemica1 properties support a role for immune complexes in 
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the pathogenesis of the disease. Finally, the similarities of joint 
pathology and the presence of immune complexes in both diseases make 
Lyme arthritis an ideal model for studying rheumatoid arthritis. 
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